Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 06, 2015 8:16 PM ET

Biotechnology

Company Overview of REGENX Biosciences, LLC

Company Overview

REGENX Biosciences, LLC, a biopharmaceutical company, develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity and target validation, creating disease models a...

1701 Pennsylvania Avenue, NW

Suite 900

Washington, DC 20006

United States

Phone:

202-785-7438

Key Executives for REGENX Biosciences, LLC

Chief Executive Officer, President and Director
Chief Financial Officer
Chief Operating Officer
Chief Medical Officer
Vice President of Legal Affairs
Compensation as of Fiscal Year 2014.

REGENX Biosciences, LLC Key Developments

REGENXBIO Inc Appoints Luke M. Beshar as Board of Director

REGENXBIO Inc. announced that Luke M. Beshar has been appointed to its board of directors effective April 15, 2015. Mr. Beshar will serve as the chairman of REGENXBIO's audit committee. Mr. Beshar brings more than 35 years of leadership experience to REGENXBIO's board. Most recently, he was Executive Vice President and Chief Financial Officer at NPS Pharmaceuticals Inc. Prior to NPS, Mr. Beshar served in leadership positions and as chief financial officer for organizations including Cambrex Corporation, Dendrite International, Expanets Inc., PNY Technologies Inc., WSR Corporation, The Genlyte Group Inc., Bairnco Corporation and Arthur Andersen & Co.

REGENX Biosciences, LLC Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 01:00 PM

REGENX Biosciences, LLC Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 01:00 PM. Venue: Metropolitan Club, One East 60th Street, New York, NY 10022, United States. Speakers: Kenneth T. Mills, Chief Executive Officer, President and Director.

REGENX Biosciences, LLC Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 01:40 PM

REGENX Biosciences, LLC Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 01:40 PM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103, United States. Speakers: Kenneth T. Mills, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
AzurTec, Inc. United States
Pivot Bio, Inc. United States
Biotic Laboratories, Inc. United States
Angiorad, L.L.C. United States
LeadScope, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 20, 2015
Dimension Therapeutics, Inc.
Private Placement
January 13, 2015
--
Merger/Acquisition
June 2, 2014
REGENX Biosciences, LLC, Worldwide License to Proprietary NAV® Vectors
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENX Biosciences, LLC, please visit www.regenxbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.